Biocorp Production Toekomstige groei

Future criteriumcontroles 5/6

De verwachting is dat Biocorp Production de winst en omzet met respectievelijk 136.3% en 47.9% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 136.8% per jaar.

Belangrijke informatie

136.3%

Groei van de winst

136.8%

Groei van de winst per aandeel

Medical Equipment winstgroei	15.4%
Inkomstengroei	47.9%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	11 Oct 2023

Recente toekomstige groei-updates

Biocorp Production (EPA:ALCOR) Just Reported And Analysts Have Been Cutting Their Estimates

Apr 11

Recent updates

Would Biocorp Production (EPA:ALCOR) Be Better Off With Less Debt?

Dec 08

What Does The Future Hold For Biocorp Production (EPA:ALCOR)? These Analysts Have Been Cutting Their Estimates

Jun 26

Biocorp Production (EPA:ALCOR) Just Reported And Analysts Have Been Cutting Their Estimates

Apr 11

What Type Of Shareholders Own The Most Number of Biocorp Production (EPA:ALCOR) Shares?

Mar 04

Is Biocorp Production's (EPA:ALCOR) Share Price Gain Of 179% Well Earned?

Jan 10

What Type Of Shareholders Own The Most Number of Biocorp Production (EPA:ALCOR) Shares?

Nov 18

Winst- en omzetgroeiprognoses

ENXTPA:ALCOR - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2025	45	18	10	N/A	1
12/31/2024	24	1	0	N/A	1
12/31/2023	19	0	-2	N/A	1
6/30/2023	13	-2	N/A	N/A	N/A
3/31/2023	12	-1	N/A	N/A	N/A
12/31/2022	12	-1	-1	0	N/A
9/30/2022	11	-1	-1	0	N/A
6/30/2022	10	-1	-1	1	N/A
3/31/2022	10	0	-1	0	N/A
12/31/2021	10	0	-1	0	N/A
9/30/2021	9	-1	-3	-1	N/A
6/30/2021	8	-2	-4	-2	N/A
3/31/2021	8	-1	-3	-1	N/A
12/31/2020	8	-1	-3	0	N/A
9/30/2020	8	-1	-1	1	N/A
6/30/2020	7	-1	1	3	N/A
3/31/2020	8	0	1	2	N/A
12/31/2019	8	1	1	2	N/A
9/30/2019	8	0	-2	-1	N/A
6/30/2019	7	-1	-5	-4	N/A
3/31/2019	6	-3	-5	-5	N/A
12/31/2018	4	-5	-6	-5	N/A
9/30/2018	4	-6	-5	-4	N/A
6/30/2018	3	-8	-4	-4	N/A
3/31/2018	3	-8	-5	-4	N/A
12/31/2017	2	-8	-5	-4	N/A
9/30/2017	2	-6	-5	-4	N/A
6/30/2017	2	-5	-5	-4	N/A
3/31/2017	3	-5	N/A	-4	N/A
12/31/2016	3	-4	N/A	-3	N/A
9/30/2016	3	-4	N/A	-3	N/A
6/30/2016	3	-4	N/A	-3	N/A
3/31/2016	3	-2	N/A	-3	N/A
12/31/2015	3	-1	N/A	-3	N/A
12/31/2014	2	0	N/A	-1	N/A
12/31/2013	2	0	N/A	N/A	N/A
12/31/2012	2	N/A	N/A	N/A	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat ALCOR de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 0.7% ).

Winst versus markt: Er wordt verwacht dat ALCOR de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat ALCOR binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van ALCOR ( 47.9% per jaar) zal naar verwachting sneller groeien dan de markt French ( 5.6% per jaar).

Hoge groei-inkomsten: De omzet van ALCOR ( 47.9% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ALCOR naar verwachting over 3 jaar hoog zal zijn

Biocorp Production Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates increase by 38%

Consensus forecasts updated

Price target increased to €36.53

Biocorp Production (EPA:ALCOR) Just Reported And Analysts Have Been Cutting Their Estimates

Recent updates

First half 2023 earnings released: €0.86 loss per share (vs €0.53 loss in 1H 2022)

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire a 64.4% stake in Biocorp Production (ENXTPA:ALCOR) for €99.1 million.

Novo Nordisk Enters into Exclusive Negotiations to Acquire A Controlling Stake in Bicorp, to Be Followed by A Tender Offer on All Remaining Shares

Full year 2022 earnings released

Biocorp Production to Report First Half, 2023 Results on Sep 28, 2023

Biocorp Production announced that it has received €2.5 million in funding from Vatel Capital SAS

Would Biocorp Production (EPA:ALCOR) Be Better Off With Less Debt?

Biocorp Production Obtains 510(K) FDA Clearance for Mallya

Less than half of directors are independent

First half 2022 earnings released: EPS: €0 (vs €0.28 loss in 1H 2021)

Consensus EPS estimates increase by 38%

What Does The Future Hold For Biocorp Production (EPA:ALCOR)? These Analysts Have Been Cutting Their Estimates

Consensus forecasts updated

Price target increased to €36.53

Less than half of directors are independent

Full year 2021 earnings: Revenues miss analyst expectations

First half 2021 earnings released

Biocorp Production (EPA:ALCOR) Just Reported And Analysts Have Been Cutting Their Estimates

Full year 2020 earnings released

New 90-day high: €30.60

What Type Of Shareholders Own The Most Number of Biocorp Production (EPA:ALCOR) Shares?

BIOCORP Announces the Signature of New Partnerships with Health2sync and SocialDiabetes

New 90-day high: €30.40

Is Biocorp Production's (EPA:ALCOR) Share Price Gain Of 179% Well Earned?

Biocorp Production to Report Fiscal Year 2020 Results on Apr 08, 2021

What Type Of Shareholders Own The Most Number of Biocorp Production (EPA:ALCOR) Shares?

BIOCORP Announces Launch of Mallya

New 90-day high: €33.00

Biocorp Production Announces Partnership with AARDEX Group to Extend Smart Solutions for Precision Medication Adherence

New 90-day high - €28.50

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven